TC-PTP inhibitors as APC activators for immunotherapy
US10005804B2 · kind B2 · utility
2Cited by
0References
9Claims
0Family size
Inventors
Key dates
| Filing date | Sep 20, 2017 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Sep 20, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.